Psoriasis patients who are on long-term methotrexate therapy are regularly screened for hepatic fibrosis, most often with a liver biopsy — sometimes multiple times.

Now, a new study in JAMA Dermatology raises the possibility of adopting the nonalcoholic steatohepatitis (NASH) FibroSure test to detect hepatic fibrosis in psoriasis patients, which may minimize the number of liver biopsies these patients need.